Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.59 |
| ▸ | ACE | P12821 | 8/20 | 0.59 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16232066 | 0.88 | MME (0.53) | MMEACE | |
| SCHEMBL18970022 | 0.86 | REN (0.48) | MMEACESRRPSAT1 | |
| SCHEMBL28586322 | 0.86 | MME (0.56) | MMEACESRRPSAT1 | |
| SCHEMBL28632127 | 0.86 | MME (0.56) | MMEACESRRPSAT1 | |
| SCHEMBL28586326 | 0.86 | MME (0.56) | MMEACESRRPSAT1 | |
| SCHEMBL24404055 | 0.84 | GPR88 (0.49) | MMEACESRRPSAT1 | |
| SCHEMBL609953 | 0.84 | GPR88 (0.49) | MMEACESRRPSAT1 | |
| SCHEMBL21572784 | 0.84 | GPR88 (0.49) | MMEACESRRPSAT1 | |
| SCHEMBL598890 | 0.84 | GPR88 (0.49) | MMEACESRRPSAT1 | |
| SCHEMBL18059571 | 0.84 | GPR88 (0.49) | MMEACESRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885ACE 92/4885SRR 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.